ישראל - עברית - Ministry of Health

inovamed ltd - epirubicin hydrochloride - תמיסה להזרקה - epirubicin hydrochloride 2 mg / 1 ml - epirubicin - epirubicin - for the treatment of wide spectrum of neoplastic diseases including breast carcinoma, lung carcinoma high doses, ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection. i.v. administration for the treatment of advanced bladder carcinoma.

ישראל - עברית - Ministry of Health

mbi pharma ltd., israel - epirubicin hydrochloride - תמיסה להזרקה - epirubicin hydrochloride 50 mg / 25 ml - epirubicin

ישראל - עברית - Ministry of Health

mbi pharma ltd., israel - epirubicin hydrochloride - תמיסה להזרקה - epirubicin hydrochloride 50 mg / 25 ml - epirubicin

ישראל - עברית - Ministry of Health

novartis israel ltd - epirubicin hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - epirubicin hydrochloride 2 mg/ml - epirubicin

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - epirubicin hydrochloride 2 mg / 1 ml - solution for injection / infusion - epirubicin - for the treatment of wide spectrum of neoplastic diseases, including:- breast carcinoma- lung carcinoma - high doses- ovarian carcinoma- gastric carcinomas- soft tissue sarcoma- i.v. administration for the treatment of advanced bladder carcinoma- intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection.

ישראל - עברית - Ministry of Health

megapharm ltd - dexrazoxane as hydrochloride - אבקה להכנת תמיסה לאינפוזיה - dexrazoxane as hydrochloride 500 mg/vial - dexrazoxane - dexrazoxane - prevention of cardiotoxicity in adult women with advanced and/or metastatic breast cancer at high risk of heart failure who have received a prior cumulative dose of 300 mg/m2 of doxorubicin or a prior cumulative dose of 540 mg/m2 of epirubicin when further anthracycline treatment is required.

ישראל - עברית - Ministry of Health

novartis israel ltd - doxorubicin hydrochloride - solution for infusion - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - soft tissue and bone sarcomas, hodgkin's and non-hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms` tumor, carcinomas of the thyroid, breast, ovary, bladder, small cell bronchogenic carcinoma and neuroblastoma.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - idarubicin hydrochloride - אבקה להכנת תמיסה מרוכזת לעירוי - idarubicin hydrochloride 10 mg/vial - idarubicin - idarubicin - antimitotic and cytotoxic agent. acute non-limphocytic leukemia (anll) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients.acute limphocytic leukemia (all) as second line treatment in adults and children.

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - doxorubicin hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - to produce regression in disseminated neoplastic conditions such as: - acute lymphoblastic leukemia, - acute myeloblastic leukemia, - wilms' tumor neuroblastoma, - soft tissue and bone sarcomas, - breast carcinoma, - lymphomas of both hodgkin's and non-hodgkin's types, - bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types, - gastric carcinoma.

ישראל - עברית - Ministry of Health

j-c health care ltd - doxorubicin hydrochloride - liposome for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.